Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
20 drugs in development
By Therapeutic Area
top 5
R&D Momentum
93/100
Pipeline Velocity
75/100
Trial Completion Rate
67/100
Pipeline Concentration
28/100
Pipeline Freshness
72/100
Strategic Signals
Activity
Last 14 days
Pulse Wave Method Versus Saline Contrast Pulmonary Perfusion EIT Imaging for Detecting Pulmonary Perfusion in ARDS Patients: a Prospective Observational Study
The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors
Prospective Multicenter Validation of AI-Generated Future CT Images for Subsolid Pulmonary Nodule Progression and a Nested Silent Reader Evaluation of Simulated Surveillance Decisions
Subset-specific Metabolic Adaptation and Functional Remodeling of Gamma Delta T (γδ T) Cells in Critically Ill ICU Patients: A Single-center, Prospective, Observational Cohort Study.
Diagnosis of Infectious Pneumonia and Detection of Unusual Infections Using Medical Imaging and Artificial Intelligence
Study of Imaging Evolution of Pulmonary Nodules and Artificial Intelligence-Assisted Diagnostic and Management Strategies
The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant Tumors
Pembrolizumab Combined With MRG-003 as Neoadjuvant Treatment of EBV- Associated Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-arm, Single-center, Prospective Phase II Trial
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)